Company** | Product | Description | Indication | Status (Date) |
CANCER | ||||
Alfacell Corp. | Onconase | Cytotoxic ribonuclease; | Pancreatic cancer | Preliminary analysis of |
(NASDAQ:ACEL) | member of the super- | Phase III trials did not | ||
family of pancreatic | demonstrate survival | |||
ribonucleases | benefit over standard | |||
therapies; company has | ||||
stopped trial and will not | ||||
file NDA for this indi- | ||||
cation (7/15) | ||||
Aronex | Atragen | Liposomal formulation | Relapsed or refractory | Initiated Phase I trial in |
Pharmaceuticals | of all-trans retinoic acid; | non-Hodgkin's B cell | NHL; completed patient | |
Inc. | induces tumor cells to | lymphoma (NHL); also | enrollment in Phase II | |
differentiate into mature | acute promyelocytic | trial in PML (7/21) | ||
normal cells | leukemia (PML) | |||
Avax Technologies | M-Vax | Therapeutic vaccine; | Postsurgical treatment | Restarted Phase III trial |
Inc. | tumor cells removed | of patients with stage | (which had been halted | |
from patient, modified | III melanoma | in 10/97 to file paperwork | ||
with hapten (DNP; di- | with FDA on manufactur- | |||
nitrophenyl), then | ing data) (7/27) | |||
injected back into | ||||
patient (along with | ||||
cyclophosphamide) | ||||
Cell Pathways Inc.* | FGN-1 | Exisulind; orally active | Adenomatous poly- | Initiated open-label safety |
drug designed to induce | posis coli in children | study (7/28) | ||
apoptosis in precan- | (precancerous colonic | |||
cerous cells | polyps) | |||
Genta Inc. | G3139 | Anticode (antisense) | Hormone-resistant | Initiated new Phase I/IIa |
compound; synthetic | metastatic prostate | trial (7/14) | ||
DNA strands that bind | cancer (combination | |||
to mRNA for bcl2 gene | therapy with an andro- | |||
(proto-oncogene) | gen receptor-blocking | |||
agent) | ||||
Jenner | OncoVax-P | Cancer vaccine; incor- | Hormone-refractory | Initiated Phase II trial |
Biotherapies Inc.* | porates recombinant | prostate cancer | (7/23) | |
prostate-specific antigen | ||||
plus adjuvant in lipo- | ||||
somal formulation | ||||
Medarex Inc. | MDX-220 | Bispecific antibody | TAG-72-positive can- | Initiated Phase I/II trial |
composed of trigger | cers, including colon | (7/16) | ||
antibody and 2nd, | and prostate cancer | |||
humanized antibody | (pretreatment with | |||
that targets TAG-72 | granulocyte colony- | |||
antigen present on | stimulating factor) | |||
many cancers | ||||
NaPro | Paclitaxel | Compound extracted | Various cancers | Initiated clinical trial |
BioTherapeutics | from needles and limb | (7/9) | ||
Inc. | stock of ornamental | |||
yew trees; administered | ||||
via NaPro's Q4D | ||||
administration (which | ||||
includes 60-180 minute | ||||
infusion) | ||||
Sugen Inc. | SU 101 | Small-molecule signal | Malignant glioma | Initiated Phase III trial |
transduction inhibitor; | (7/1) | |||
specifically inhibits | ||||
platelet-derived growth | ||||
factor receptor signaling | ||||
SU 101 | Small-molecule signal | Recurrent ovarian | Initiated Phase II trial | |
transduction inhibitor; | cancer in patients who | (7/14) | ||
specifically inhibits | have failed standard | |||
platelet-derived growth | therapy | |||
factor receptor signaling | ||||
Techniclone Corp. | Oncolym | LYM-1 murine mono- | Intermediate- and high- | FDA allowed amendment |
clonal antibody to HLA- | grade refractory or | to current Phase II/III | ||
DR10 protein (cell- | relapsed non-Hodgkin's | trial protocol to include | ||
surface marker present | B cell lymphoma | NHL patients who have | ||
on 80% of lymphoma | (NHL) | failed or relapsed follow- | ||
cells), labeled with I-131 | ing treatment with other | |||
monoclonal antibodies | ||||
(7/23) | ||||
TNT | Tumor necrosis therapy; | Malignant glioma | Completed patient enroll- | |
chimeric monoclonal | (interstitial delivery) | ment in radiation dosi- | ||
antibody that targets | metry (imaging) portion | |||
DNA-associated histone | of Phase I trial (7/21) | |||
antigens, labeled with | ||||
I-131 (targets necrotic | ||||
center of tumor) | ||||
Titan | CeaVac | Anti-idiotypic mono- | Stage IV colorectal | Initiated Phase II trials |
Pharmaceuticals | clonal antibody-based | cancer | in U.S. and U.K. (7/16) | |
Inc. | vaccine; mimics CEA | |||
antigen present on many | ||||
types of cancer cells | ||||
Pivanex | Small-molecule ana- | Refractory Stage III | Initiated Phase II trial | |
logue of butyric acid | and IV non-small cell | (7/22) | ||
(naturally occurring | lung cancer | |||
substance that regulates | ||||
cell growth) | ||||
TriAb | Anti-idiotypic mono- | Metastatic breast cancer | Initiated Phase II trial | |
clonal antibody-based | in patients who have | (7/16) | ||
vaccine; mimics epitope | responded to standard | |||
on breast cancer cell- | therapy | |||
associated antigen HMFG | ||||
Vertex | Incel | Small synthetic molecule | Advanced hormone- | Initiated Phase II trial |
Pharmaceuticals | (VX-710) | designed to block both | refractory prostate can- | (7/27) |
Inc. | the MDR1 and MRP | cer (combination ther- | ||
drug-resistance mecha- | apy with prednisone | |||
nisms in chemotherapy- | and Novantrone) | |||
resistant tumor cells | ||||
Vical Inc. | — | DNA vaccine; contains | Metastatic melanoma | Initiated Phase I/II trial |
gene sequence for modi- | (sponsored by National | |||
fied melanoma antigen | Cancer Institute) (7/9) | |||
gp100 peptides (intra- | ||||
muscular or intra- | ||||
dermal administration) | ||||
CARDIOVASCULAR | ||||
Centocor Inc. and | ReoPro | Chimeric monoclonal | Heart patients under- | Results of EPISTENT clini- |
Eli Lilly and Co. | (FDA- | antibody fragment to | going stenting and | cal trials (conducted in U.S. |
(NYSE:LLY) | approved) | GPIIb/IIIa platelet | balloon angioplasty | and Canada) published |
receptor (abciximab) | in 7/11/98 The Lancet (7/9) | |||
Corvas | NIF | Neutrophil inhibitory | Ischemic stroke | Pfizer completed Phase |
International Inc. | factor (anti-inflammatory) | Ia trial (7/6) | ||
and Pfizer Inc. | ||||
(NYSE:PFE) | ||||
Genentech Inc. | Activase | Alteplase; recombinant | Acute ischemic stroke | Data safety monitoring |
(FDA- | tissue plasminogen | (administered 3-5 hours | board recommended | |
approved) | activator | from symptom onset) | termination of ATLANTIS | |
trial; interim analysis | ||||
showed lack of clinical | ||||
benefit in patients treated | ||||
after 3 hours (7/20) | ||||
GenVec Inc.* and | Gene | Direct injection of VEGF | Peripheral vascular | Initiated Phase I/II trial |
the Parke-Davis | therapy | gene (vascular endothel- | disease | at New York Hospital/ |
Research division of | ial growth factor; in adeno- | Cornell Medical Center | ||
Warner-Lambert Co.; | viral vector) into heart | (7/6) | ||
(NYSE:WLA) | muscle during cardiac | |||
bypass surgery; to induce | ||||
revascularization of | ||||
heart tissue | ||||
Interneuron | CerAxon | Citicholine sodium; | Reduction of infarct | Initiated new Phase III |
Pharmaceuticals | organic molecule that | size and improvement | trial with increased dos- | |
Inc. | consists of cytidine and | in neurological function | age and larger patient | |
choline (components | in patients with ischemic | numbers than in previous | ||
of brain cell membranes) | stroke | failed trial (7/7) | ||
Scios Inc. and | Fiblast | Trafermin; recombinant | Acute stroke | Terminated North Amer- |
Wyeth-Ayerst Lab- | human basic fibroblast | ican Phase II/III trial due | ||
oratories (division | growth factor | to unfavorable risk-to- | ||
of American Home | benefit ratio of drug vs. | |||
Products Corp.; | placebo (7/21) | |||
NYSE:AHP) | ||||
Texas | TBC 11251 | Small-molecule drug; | Moderate-to-severe | Announced preliminary |
Biotechnology | endothelin-A receptor | congestive heart failure | results of Phase IIa trial | |
Corp. | antagonist (intravenous) | (7/21) | ||
CENTRAL NERVOUS SYSTEM | ||||
Icos Corp. | Hu23F2G | Humanized monoclonal | Acute exacerbations | Initiated multidose |
antibody that blocks | in multiple sclerosis | Phase II trial (7/17) | ||
CD11/CD18-mediated cell | ||||
adhesion (inhibits move- | ||||
ment of neutrophils | ||||
from blood into tissue) | ||||
NPS | NPS 1506 | Small molecule; inter- | Neuroprotection in | Initiated Phase Ib trial |
Pharmaceuticals | acts with N-methyl-D- | stroke (administered | (7/1) | |
Inc. | aspartate (NMDA) recep- | within 48 hours) | ||
tor to block flow of | ||||
calcium into brain cells | ||||
DIABETES | ||||
Amylin | Pramlintide | Synthetic analogue of | To improve glucose | Completed patient enroll- |
Pharmaceuticals | human pancreatic | control in patients with | ment in 2 one-year | |
Inc. | hormone amylin | Type I diabetes and in | Phase III trials (7/10) | |
insulin-using patients | ||||
with Type II diabetes | ||||
Celtrix | SomatoKine | IGF-BP3 complex; | To improve glycemic | Initiated Phase II trial |
Pharmaceuticals | recombinant version | control and lower require- | (7/15) | |
Inc. | of complex formed by | ment for exogenous | ||
insulin-like growth | insulin in patients with | |||
factor-1 and its major | Type I diabetes | |||
binding protein | ||||
INFECTION | ||||
Cell Genesys Inc. | Gene | Procedure by which | HIV infection and | Reported interim results |
therapy | patient's own T cells are | AIDS (in combination | from Phase II trial at 2nd | |
collected, genetically | with antiretroviral | International Workshop | ||
modified to recognize | drugs) | on HIV Drug Resistance | ||
and destroy HIV-infected | and Treatment Strategies | |||
cells, then returned | in Lake Maggiore, Italy, | |||
to same patient | and at 12th International | |||
AIDS Conference in Geneva, | ||||
Switzerland (7/1) | ||||
Enzo Therapeutics | HGTV 43 | Genetic antisense | To stop viral pro- | Initiated Phase I trial |
Inc. (subsidiary of | medicine; insertion of | gression in HIV- | (7/13) | |
Enzo Biochem Inc.) | gene that synthesizes | infected patients | ||
antisense molecule to | ||||
HIV-1 directly into | ||||
blood cells (patient's | ||||
stem cells treated ex | ||||
vivo to render them | ||||
HIV-resistant, then | ||||
reinfused into patient) | ||||
Gilead Sciences | Preveon | Adefovir dipivoxil; | HIV infection and | Presented results of |
Inc. | reverse transcriptase | AIDS (combination | Phase II/III trial at AIDS | |
inhibitor (oral dosage) | therapy with anti- | conference (7/1) | ||
retroviral drugs) | ||||
Interferon | Alferon N | Highly purified, multi- | Hepatitis C virus (HCV) | Completed Phase III |
Sciences Inc. | Injection | species, natural-source | infection in previously | trial (7/23) |
(FDA- | human alpha interferon | untreated patients | ||
approved) | ||||
Alferon N | Highly purified, multi- | HIV infection and | Completed treatment | |
Injection | species, natural-source | AIDS (combination | phase of open-label con- | |
(FDA- | human alpha interferon | therapy with anti- | tinuation study of Phase | |
approved) | retroviral drugs) | III trial (7/23) | ||
Alferon N | Highly purified, multi- | HIV/HCV co-infection | Company will add more | |
Injection | species, natural-source | clinical centers to Phase | ||
(FDA- | human alpha interferon | II trial (7/23) | ||
approved) | ||||
NeXstar | MiKasome | Liposomal formulation | Treatment of compli- | Initiated patient enroll- |
Pharmaceuticals | of antibiotic amikacin | cated urinary tract | ment for 2nd arm of on- | |
Inc. | infections | going Phase II trial (7/8) | ||
MiKasome | Liposomal formulation | Treatment of nosoco- | Initiated 3rd Phase II | |
of antibiotic amikacin | mial (hospital-acqui- | trial (7/13) | ||
red) infections | ||||
SmithKline | LYMErix | Recombinant OspA | Prevention of Lyme | Clinical trial results pub- |
Beecham plc | vaccine (outer surface | disease (both definitive | lished in 7/23/98 issue of | |
(NYSE:SBH; U.K.) | protein A; antigen | disease and asympto- | The New England | |
from tick-borne bac- | matic infection) | Journal of Medicine | ||
terium Borrelia burg- | (7/23) | |||
dorferi, which causes | ||||
the infection) | ||||
Triangle | FTC | Nucleoside reverse | HIV infection and | Reported data from Phase |
Pharmaceuticals | transcriptase inhibitor | AIDS | I/II monotherapy trial at | |
Inc. | AIDS conference (7/1) | |||
U.S. Bioscience Inc. | Lodenosine | FddA; acid-stable | HIV infection and | Presented data from Phase |
purine-based reverse | AIDS | I trial (sponsored by | ||
transcriptase inhibitor | National Cancer Institute) | |||
at AIDS conference (7/2) | ||||
MISCELLANEOUS | ||||
Alexion | 5G1.1 | C5 complement inhib- | Rheumatoid arthritis | Initiated Phase I/II trial |
Pharmaceuticals | itor; humanized mono- | (7/7) | ||
Inc. | clonal antibody designed | |||
to inhibit complement | ||||
activation and reduce | ||||
inflammation over pro- | ||||
longed period of time | ||||
Alexion | 5G1.1 | C5 complement inhib- | Systemic lupus | Initiated Phase I/II trial |
Pharmaceuticals | itor; humanized mono- | erythematosus | (7/23) | |
Inc. | clonal antibody designed | |||
to inhibit complement | ||||
activation and reduce | ||||
inflammation over pro- | ||||
longed period of time | ||||
Amarillo | — | Low-dose oral alpha | Fibromyalgia syndrome | Initiated Phase II trial |
Biosciences Inc. | interferon (natural) | (7/9) | ||
Anergen Inc. and | AnergiX | Peptide vaccine; com- | Established rheumatoid | Initiated Phase I trial |
Organon NV | bines peptide derived | arthritis in patients who | (7/7) | |
(the Netherlands) | from human cartilage- | are taking methotrexate | ||
derived glycoprotein | ||||
(HCgp39) with AnergiX | ||||
technology (selectively | ||||
inactivates T cells that | ||||
cause inflammation) | ||||
BioTransplant Inc. | AlloMune | Process involves mixing | Kidney transplantation | FDA cleared protocol for |
System | bone marrow from | Phase I/II trial (7/13) | ||
patient and donor to | ||||
create chimeric bone | ||||
marrow; allows trans- | ||||
plants of mismatched | ||||
kidneys without use of | ||||
immunosuppressive | ||||
drugs | ||||
BioTransplant Inc. | BTI-322 | Murine monoclonal | Treatment of acute | Reported results of Phase |
and MedImmune Inc. | antibody that binds to | graft-vs.-host disease in | II trial at 17th annual | |
CD2 antigen receptor | allogeneic bone marrow | World Congress Meeting | ||
on T cells and natural | transplant patients | of the Transplantation | ||
killer cells | unresponsive to steroid | Society in Montreal | ||
therapy | (7/15) | |||
Celgene Corp. | Thalidomid | Thalidomide; thought | AIDS-associated | Results from ongoing, |
(FDA- | to act by modulating | weight loss (cachexia) | open-label study present- | |
approved) | levels of tumor necrosis | ed at AIDS conference | ||
factor-alpha | (7/27) | |||
Circe Biomedical | HepatAssist | Extra-corporeal bio- | To provide temporary | FDA cleared protocol for |
Inc. (wholly owned | artificial liver system | essential liver functions | Phase II/III trial (in U.S. | |
subsidiary of W.R. | consisting of membranes | in patients suffering | and Europe) (7/23) | |
Grace; NYSE:GRA) | and porcine liver cells | from acute liver failure | ||
Connetics Corp. | Clobetasol | Foam formulation of | Severe, corticosteroid- | Initiated Phase III trial |
ViaFoam | 0.05% clobetasol | responsive dermatoses | (7/8) | |
proprionate | of the scalp, including | |||
psoriasis | ||||
Discovery | Surfaxin | Sinapultide; lung sur- | Acute respiratory | Initiated pivotal Phase II/ |
Laboratories Inc. | factant containing the | distress syndrome | III trial (7/14) | |
peptide KL4 (a 21- | from direct causes | |||
amino-acid peptide | (i.e., non-sepsis | |||
modeled after the SP-B | causes such as | |||
protein in the human | pneumonia) | |||
surfactant system) | ||||
Ergo Science Corp. | Ergoset | Oral formulation of | Clinical obesity | Completed patient enroll- |
Tablets | bromocriptine (ergot | ment in Phase II trial | ||
alkaloid; generic | (7/21) | |||
dopamine agonist) | ||||
Synsorb Biotech | Synsorb Cd | Product that binds to | Treatment for recurring | FDA cleared protocol for |
Inc. (Canada) | toxins secreted by | or relapsing antibiotic- | Phase II trial (7/22) | |
bacteria in the gastro- | associated diarrhea | |||
intestinal tract | ||||
NOTES: | ||||
* Private companies are indicated with an asterisk. | ||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 10-11. |